Riskpilot← Back to searchSign inGet full accessNefecon AB
ABActiveOrg 5566049069StockholmResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20010 employees
Revenue 2025
SEK 0
EBITDA margin
—
Equity ratio
100.0%
Financial strength
Net profit 2025
SEK 0
0 employees
| Revenue | SEK 0 | — |
| EBITDA | — | — |
| Net profit | SEK 0 | — |
| Total assets | SEK 105K | +0% |
| Equity | SEK 105K | +0% |
| Employees | 0 | — |
Legal name
Nefecon AB
Org number
5566049069
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
11 januari 2001
Share capital
SEK 100 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2025-03-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget skall, direkt eller genom dotterbolag, bedriva forskning och utveckling samt tillverkning och försäljning av läkemedel och medicintekniska produkter, äga och förvalta aktier och andra värdepapper samt annan lös och fast egendom, ävensom idka därmed förenlig verksamhet.
Address
Stockholm
Phone
+4684113005
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | −356 | −536 | −313 | 19 | −1 | −1 | — | — | — | — |
| Depreciation & amort. | −0 | −0 | −0 | −224 | −2 014 | −0 | −0 | −0 | −0 | −0 |
| EBIT | −356 | −536 | −313 | −205 | −2 015 | −1 | 0 | 0 | 0 | 0 |
| Net financials | — | — | — | — | — | — | — | — | — | — |
| Profit before tax | −356 | −536 | −313 | −205 | −2 015 | −1 | 0 | 0 | 0 | 0 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −356 | −536 | −313 | −205 | −2 015 | −1 | 0 | 0 | 0 | 0 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 2 404 | 2 334 | 2 295 | 2 071 | 106 | 105 | 105 | 105 | 105 | 105 |
| Equity | 816 | 2 288 | 1 975 | 1 771 | 106 | 105 | 105 | 105 | 105 | 105 |
| Long-term debt | 1 567 | 0 | 300 | 300 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 21 | 46 | 20 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total debt | 1 588 | 46 | 320 | 300 | — | — | — | — | — | — |
EBITDA margin
0.0%
This company
15.8%
Market median
-100% vs market
20152025
Equity ratio
100.0%
This company
38.2%
Market median
+162% vs market
20152025
Return on equity
0.0%
This company
18.4%
Market median
-100% vs market
20152025
Net profit margin
0.0%
This company
8.1%
Market median
-100% vs market
20152025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20152025
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20152025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-01-01 – 2025-03-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
No data on file.
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2022 | — | — | |
| Deputy Board Member | 2020 | — | — | |
| Deputy Board Member | 2020 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Calliditas Therapeutics AB | Company | 100.0% | 100.0% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
ASAHI KASEI CORPORATION
Nefecon AB Board members of Nefecon AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Bengt Åke Julander | Board of Directors | 0 companies |
| Carl Fredrik Johansson | Board of Directors | 0 companies |
| Frans Peter Günther Einarsson | Deputy Board Member | 0 companies |
| Johan Erik Häggblad | Deputy Board Member | 0 companies |